pH Environmental Acquires TNI BioTech

ph Environmental Inc AnnouncesCompletion of Merger with TNI BioTech Inc., and Trading on OTC Markets PinkUnder Symbol RTCI

pH Environmental Inc (the “Company”) (OTC:RTCI.PK ) announced today that it has completed its mergerwith TNI BioTech, Inc. The Company submitted paperwork to FINRA to change itsname to TNI BioTech, Inc., and has requested a symbol change as the Company iscurrently trading on the OTC Markets Pink under the symbol "RTCI."The merger was completed in a restricted stock exchange transaction on April24, 2012. Reorganization is now complete and the management of pH EnvironmentalInc has resigned. Dr. Eugene Youkills, the President of TNI BioTech IP, Inc.,will assume control of the Company along with the Board of Directors of TNIBioTech IP, Inc. www.tnibiotech.com

Dr. EugeneYoukills, President of TNI BioTech, Inc., and TNI BioTech IP, Inc., said, "Weare very pleased to complete the merger. It has taken a significant amount ofwork but we believe, with our team of experts, we can pursue our goal ofcommercializing our products. We have a strong Company and will hit the groundrunning and hope to be able to provide our shareholders with excitingdevelopments.”

About TNI BioTech

TNI BioTech,Inc. is a biotechnology company researching new treatments and methods fortreatment of cancer, HIV/AIDS, and certain other autoimmune and infectiousdiseases. One of the approaches is based on patent rights obtained fromNicholas P. Plotnikoff who has conducted specialized research activitiesdirected toward the study of cytokines, which are hormones naturally producedby the immune system. The primary cytokine, among many others currently beingstudied by TNI, is methionine enkephalin (“MENK”). MENK, in both non-humanstudies and human clinical trials, has been shown to stimulate the immunesystem.

Management believes that animmune system stimulator, such as MENK, is of tremendous value to medicinegiven that many diseases lower the body’s immune response and cause a lack ofresistance to the progress of the disease.

However, even thoughManagement considers any condition that results in altered-immune response atarget for investigation, the Company will most likely pursue additionalinvestigations for MENK as a valuable candidate in the treatment of thefollowing: 

·  Autoimmune states such asrheumatoid arthritis and multiple sclerosis;

·  As an adjunct toantibiotics in the treatment of infectious diseases;

·  In patients undergoingchemotherapy, radiation treatments or surgery; and

·  In wound healing, herpesviral infections, and in treatment for the elderly.

SPECIAL NOTEREGARDING FORWARD-LOOKING STATEMENTS: This press release includes various"forward-looking statements" within the meaning of Section 27A of theSecurities Act of 1933, as amended, and Section 21E of the Securities ExchangeAct of 1934, as amended, which represent the Company’s expectations or beliefsconcerning future events. Statements containing expressions such as “believes,”“anticipates,” “intends,” or “expects,” used in the Company's press releasesand in Disclosure Statements and Reports filed with the Over The Counter Marketsthrough the OTC Disclosure and News Service are intended to identifyforward-looking statements. All forward-looking statements involve risks anduncertainties. Although the Company believes its expectations are based uponreasonable assumptions within the bounds of its knowledge of its business andoperations, there can be no assurances that actual results will not differmaterially from expected results. The Company cautions that these and similarstatements included in this report are further qualified by important factorsthat could cause actual results to differ materially from those in theforward-looking statements. Readers are cautioned not to place undue relianceon forward-looking statements, which speak only as of the date thereof. TheCompany undertakes no obligation to publicly release any revisions to suchforward-looking statements to reflect events or circumstances after the datehereof.

See www.tnibiotech.com for moreinformation.

Contact: Global Investment Media